QT Prolongation

Key Points

• The study aims to evaluate the effects of various drug interactions on QT prolongation and associated cardiovascular risks.
• Randomized double-blind trial with a diverse population being monitored
• Participants underwent detailed electrocardiogram assessments
• Data was analyzed to identify significant QT prolongation events
• QT prolongation was observed in 25% of patients taking combination therapy, with a hazard ratio of 2.1 (95% CI 1.5-3.0, P<0.001).
• Significant drug interactions were identified, indicating increased cardiovascular risks associated with certain medications.